VITROLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 163.3 SEK | +3.62% |
|
-0.24% | -16.13% |
| Apr. 25 | Vitrolife AB Approves Dividend for the Financial Year 2023 | CI |
| Apr. 18 | Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest | DJ |
Presenter SpeechPatrik Tolf (Executives)Good morning. Welcome to the Capital Markets Day for t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-07-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
163.3
SEK
Average target price
231.7
SEK
Spread / Average Target
+41.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.13% | 2.02B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- VITR Stock
- News Vitrolife AB
- Transcript : Vitrolife AB - Analyst/Investor Day
